Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Nucleic acid molecules encoding non-naturally occurring T cell receptors and cells thereof
US9068178B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9068178-B2 |
| Application number | US-201313947580-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 22, 2013 |
| Priority date | Jul 3, 2009 |
| Publication date | Jun 30, 2015 |
| Grant date | Jun 30, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A T cell receptor (TCR) having the property of binding to the gp100 YLEPGPVTA peptide-HLA-A2 complex and comprising a TCR alpha variable domain and/or a TCR beta variable domain, characterized in that the domains are mutated relative to a TCR having the extracellular alpha and beta chain sequences SEQ ID NOs: 2 and that the TCR has a binding affinity for, and/or a binding half-life for, the YLEPGPVTA-HLA-A2 complex at least double that of a reference TCR. Embodiments of the invention such as the use of such TCRs in adoptive therapy, and fusions of such TCRs with therapeutic agents are also described.
First claim
Opening claim text (preview).
What is claimed is: 1. A DNA or RNA molecule encoding a T cell receptor (TCR) that binds to a YLEPGPVTA (SEQ ID NO: 1)-HLA-A2 complex comprising a TCR alpha chain variable domain and a TCR beta chain variable domain, wherein: (a) the alpha chain variable domain has (i) at least 90% sequence identity to the amino acid sequence comprising amino acids 1 to 109 of SEQ ID NO: 2, or (ii) at least 90% sequence identity to the amino acids 1 to 109 of SEQ ID NO: 2 and has a mutation at…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9068178B2 cover?
- A T cell receptor (TCR) having the property of binding to the gp100 YLEPGPVTA peptide-HLA-A2 complex and comprising a TCR alpha variable domain and/or a TCR beta variable domain, characterized in that the domains are mutated relative to a TCR having the extracellular alpha and beta chain sequences SEQ ID NOs: 2 and that the TCR has a binding affinity for, and/or a binding half-life for, the YLE…
- Who is the assignee on this patent?
- Immunocore Ltd, Immunocore Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K14/7051. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).